What are the latest advances in aging research and drug discovery?

What are the main challenges in aging research and drug R&D?

Challenge n°1: Understand the complex nature of aging

Aging is a complex process influenced by a combination of environmental and endogenous factors. Throughout an individual’s lifetime, various environmental exposures contribute to a decrease in body’s ability to repair its cellular damage. While scientists have made progress in identifying the hallmarks of aging, there is an ongoing need for a more comprehensive understanding of the intricate molecular, cellular, and physiological changes associated with aging.¹https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405986/ Unravelling these complexities is crucial for developing targeted interventions that can effectively slow down or reverse the aging process.

Challenge n°2: Design and run appropriate clinical trials in geriatric patients

Developing drugs for geriatric patients poses multifaceted challenges. Older individuals often present with multiple co-morbidities, making it difficult to target a single disease with a one-size-fits-all approach. Clinical trials encounter additional difficulties in assessing functional outcomes, which are vital for understanding how interventions impact the overall well-being of older individuals.²https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405986/ Moreover, the exclusion of frail individuals from trials not only limits the generalizability of findings, but also overlooks the population most in need of new therapeutic options related to aging.³https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001314/ Overcoming these challenges requires a more inclusive and tailored approach to clinical trials that reflects the real-world complexities of geriatric health.

Challenge n°3: Develop the recognition of aging conditions by regulatory bodies

A significant hurdle in aging research and drug development lies within the regulatory framework. Many conditions associated with aging are not formally recognized by regulatory bodies, creating doubt about whether proposed indications will be accepted.⁴https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001314/ The criteria for recognizing a condition, as outlined by agencies like the FDA, often lack clear guidance when it comes to age-related problems.⁵https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001314/ This regulatory challenge complicates the approval process for drugs targeting conditions prevalent in geriatric patients. Bridging this gap requires efforts to establish clearer guidelines and recognition criteria that align with the unique characteristics of age-related health issues.

Despite the many challenges, aging research in drug R&D has evolved significantly in recent years, driven by advances in our understanding of the biology of aging, technological innovations, and new approaches to drug discovery.

Discover how our team can support you in your projects related to Healthy Aging >

4 examples of the latest advancements in aging research and drug discovery

Example n°1: Geroscience and targeting aging mechanisms

Recent advances in aging research have established the twelve interconnected hallmarks of aging which are comprised of genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis.⁶https://www.sciencedirect.com/science/article/pii/S0092867422013770 This discovery has provided insights into the biological mechanisms underlying the aging process. Geroscience, the interdisciplinary field that investigates the relationship between aging and chronic diseases, emphasizes aging as a target for therapeutic intervention. By understanding the core biological mechanisms, researchers aim to develop drugs that counteract the accumulation of damage associated with aging.⁷https://www.mdpi.com/1422-0067/24/10/8515

Example n°2: Genetic insights and longevity

Genetic studies involving loss-of-function and gain-of-function mutations have identified genes crucial for controlling lifespan. For example, the CDGSH iron−sulphur domain 2 (CISD2) gene, when overexpressed, shows promise in improving age-associated conditions, suggesting that pharmacological activation of CISD2 late in life could promote longevity.⁸https://www.mdpi.com/1422-0067/24/10/8515 These genetic insights provide valuable targets for drug development in the quest to extend healthy aging.

Example n°3: “AI biomarkers” and drug discovery

The integration of modern AI algorithms into aging research has revolutionized the field. AI enables the development of age predictors and biomarkers, offering new possibilities for analysing dynamic and static data types. AI biomarkers of aging provide a holistic view of biological processes, aiding in the identification of key features and potential drug targets.⁹https://pubmed.ncbi.nlm.nih.gov/30472217/ The seamless integration of AI into aging research holds the potential to enhance the credibility and prominence of longevity biotechnology in the healthcare and pharmaceutical industry.

Example n°4: Disease-specific interventions

Recent advancements in anti-aging treatment development emphasize specific strategies for conditions associated with aging. For example, studies are investigating common mechanisms linking Type 2 diabetes and Alzheimer’s disease, suggesting interventions that could simultaneously address both conditions.¹⁰https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947865/ Moreover, researchers are working on pharmacological and nutraceutical interventions (i.e., nutrient-rich dietary substances offering health benefits beyond basic nutrition) aimed at reducing illness duration and prolonging a healthy, disease-free life.

Private companies are investing heavily in aging research, creating many business opportunities. The global population is getting older, with the number of people aged 65 and older expected to double by 2050.¹¹https://www.un.org/development/desa/dspd/wp-content/uploads/sites/22/2023/01/2023wsr-chapter1-.pdf This increase in the geriatric population will increase the demand for treatments that improve quality of life and reduce healthcare costs. Venture capital firms (e.g., Longevity Venture Partners), biotechnology companies (e.g., BioAge Labs), and tech giants like Google (through Calico) and Jeff Bezos (through Altos Labs) are investing in the field.¹²https://www.pharmaceutical-technology.com/features/billionaires-anti-ageing-research/?cf-view  Large pharmaceutical players are also getting involved to expand their offers and address the underlying aging-related mechanisms of diseases like Alzheimer’s and diabetes.

While challenges persist, addressing the multifaceted nature of aging, considering more inclusive clinical trials, and navigating regulatory frameworks will be essential for progress in this field. The collaborative efforts of pharmaceutical, biotechnology, and consumer companies, as seen in initiatives like the Aging Research and Drug Discovery conference series, show a commitment to making aging research a priority.¹³https://agingpharma.org/ 

In conclusion, the convergence of cutting-edge research, technological innovation, and a commitment to understanding and addressing aging provides a hopeful outlook for the future. As the scientific community continues to solve the mysteries of aging, the potential for interventions that extend lifespan and enhance the quality of life becomes increasingly promising. Alcimed can assist you in proactively addressing challenges in the anti-aging field and staying ahead of emerging trends. Don’t hesitate to contact our team!

About the Author:

Mikka, Healthcare Consultant in Alcimed’s Healthcare team in Germany